A re-examination of the difluoromethylenesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 14, 2008, Pages 6764-6777

  Hussain, Munawar ^a,b   Ahmed, Vanessa ^a   Hill, Bryan ^a   Ahmed, Zaheer ^b   Taylor, Scott D ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Non peptidyl inhibitors; Phosphotyrosine mimics; PTP1B

Indexed keywords

[2 BROMO 4 (4' BROMO 3' SULFAMOYLBIPHENYL 4 YLMETHYL SULFANYLMETHYL)PHENYL] METHANESULFONATE; [2 BROMO 4 (4' BROMO 3' SULFAMOYLBIPHENYL 4 YLMETHYL SULFANYLMETHYL)PHENYL]DIFLUOROMETHANESULFONATE; [2 BROMO 4 [4' BROMO 3' (DIFLUOROSULFAMOYLMETHYL)BIPHENYL 4 YLMETHYLSULFANYLMETHYL]PHENYL]DIFLUOROMETHANESULFONIC ACID; [[2 BROMO 4 (4' BROMO 3' SULFAMOYLBIPHENYL 4 YLMETHYL SULFANYLMETHYL) PHENYL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[2 BROMO 4 [4' BROMO 3' DIFLUOROSULFAMOYLMETHYL)BIPHENYL 4 YLMETHYLSULFANYLMETHYL]PHENYL]DIFLUOROMETHYL]PHOSPHONIC ACID; DIFLUOROMETHYLENESULFONIC ACID; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION;

ANIMALS; ANTI-OBESITY AGENTS; CLODRONIC ACID; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR MIMICRY; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47349122949     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.05.062     Document Type: Article

References (43)

1. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., and Mustelin T. Cell 117 (2004) 699
2. Taylor S.D. Curr. Top. Med. Chem 3 (2002) 759
3. Taylor S.D., and Hill B. Exp. Opin. Invest. Drugs 13 (2004) 199
4. Ramachandran C., and Kennedy B. Curr. Top. Med. Chem. 3 (2002) 749
5. Burke T.R., and Lee K. Acc. Chem. Res. 36 (2003) 426
6. Burke T.R., Kole H.K., and Roller P.P. Biochem. Biophys. Res. Commun. 204 (1994) 129
7. Kole H.K., Akamatsu M., Ye B., Yan X., Barford D., Roller P.P., and Burke T.R. Biochem. Biophys. Res. Commun. 209 (1995) 817
8. Chen L., Wu L., Otaka A., Smyth M.S., Roller P.R., Burke T.R., den Hertog J., and Zhang Z.-Y. Biochem. Biophys. Res. Commun. 216 (1995) 976
9. Huyer G., Kelly J., Moffat J., Zamboni R., Jia Z., Gresser M.J., and Ramachandran C. Anal. Biochem. 258 (1998) 19
10. Romsicki Y., Reece M., Gauthier J.-Y., Asante-Appiah E., and Kennedy B.P. J. Biol. Chem. 279 (2004) 12868
11. Kotoris C.C., Chen M.-J., and Taylor S.D. Bioorg. Med. Chem. Lett. 8 (1998) 3275
12. Leung C., Lee J., Meyer N., Jia C., Grzyb J., Liu S., Hum G., and Taylor S.D. Bioorg. Med. Chem. 10 (2002) 2309
13. Desmarais S., Jia Z., and Ramachandran R. Arch. Biochem. Biophys. 354 (1998) 225-231
14. Burke T.R., Ye B., Yan X., Wang S., Jia Z., Chen L., Zhang Z.-Y., and Barford D. Biochemistry 35 (1996) 15898
15. Gao Y., Wu L., Luo J.H., Guo R., Yang D., Zhang Z.-Y., and Burke T.R. Bioorg. Med. Chem. Lett. 10 (2000) 923
16. Sing, L. C.; Lau, C. K.; Therien, M.; Gauthier, J.-Y.; Bayly, C.; Dufresne, C.; Fortin, R.; Leblanc, Y. International Application, Patent Cooperation Treaty Patent WO 2001/70753.
17. Lau C.K., Bayly C.I., Gauthier J.-Y., Li C.S., Therien M., Asante-Appiah E., Cromlish W., Boie Y., Forghani F., Desmarais S., Wang Q., Skorey K., Waddleton D., Payette P., Ramachandran C., Kennedy B.P., and Giovana Scapin G. Bioorg. Med. Chem. Lett. 14 (2004) 1043
18. Dufresne C., Roy P., Wang Z., Asante-Appiah E., Cromlish W., Boie Y., Forghani F., Desmarais S., Wang Q., Skorey K., Waddleton D., Ramachandran C., Kennedy B.P., Xu L., Gordon R., Chan C.C., and Leblanc Y. Bioorg. Med. Chem. Lett. 14 (2004) 1039
19. Julien S.G., Dube N., Read M., Penney J., Paquet M., Yongxin Han Y., Brian P Kennedy B.P., Muller W.J., and Tremblay M.L. Nat. Genet. 39 (2007) 338
20. Cromlish W.A., Tang M., Kyskan R., Tran L., and Kennedy B.P. Biochem. Pharmacol. 72 (2006) 1279
21. Differding E., Duthaler R.O., Kreiger A., Ruegg G.M., and Schmit C. Synlett (1991) 395
22. Taylor S.D., Kotoris C., Dinaut A.N., and Chen M.-J. Tetrahedron 54 (1998) 1691
23. Taylor S.D., Dinaut A.N., Thadini A.N., and Huang Z. Tetrahedron Lett. 45 (1996) 8089
24. Benzyl bromide 21 has been prepared in 77% yield by refluxing a solution of 3-bromo-4-methylbenzoic acid methyl ester, N-bromosuccinimide, and cat. benzoyl peroxide in carbon tetrachloride for 10 h. See: Curran, D. P.; Yang, F.; Cheong, J.-h. J. Am. Chem. Soc. 2002, 124, 14993. We have found that compound 21 can be prepared in a 93% yield by subjecting a refluxing solution of 3-bromo-4-methylbenzoic acid methyl ester, N-bromosuccinimide, and cat. benzoyl peroxide in benzene to a 250 W lamp for 6 h.
25. Kotoris C., Chen M.-J., and Taylor S.D. J. Org. Chem. 63 (1998) 8052
26. Liu S., Dockendorf C., and Taylor S.D. Org. Lett. 3 (2001) 1571
27. Petrow V., Stephenson O., and Wild A.M. J. Pharm. Pharmacol. 12 (1960) 705
28. Kiang Y.-H., Gardner G.B., Lee S., and Xu Z. J. Am. Chem. Soc. 122 (2000) 6871
29. Liu Y., Ahmed V., Hill B., and Taylor S.D. Org. Biomol. Chem. 3 (2005) 3329
30. Hill B., Liu Y., and Taylor S.D. Org. Lett. 6 (2004) 4285
31. Montalibet J., Skorey K.I., and Kennedy B.P. Methods 35 (2005) 2
32. m of the substrate, DIFMUP, under our conditions was found to be the same (5 μM) as that determined by MerckFrosst in the absence of DMSO (see Ref. 20).
33. 3Na)OH and standard manual Fmoc solid-phase peptide synthesis techniques. See:. Miranda M.T.M., Liddle R.A., and Rivier J.E. J. Med. Chem. 36 (1993) 1681
34. It is also possible that this large difference in potency between the DFMS and DFMP inhibitors is because the DFMP group is dianionic at pH 6.5 and PTP1B prefers to bind the dianionic DFMP-based inhibitors as opposed to the monoanionic DFMS-based inhibitors. However, as mentioned earlier, previous studies (see Refs. 5c and 10) suggest that PTP1B binds the monoanionic and dianionic forms of DFMP-bearing inhibitors equally well.
35. Trepka R.D., Harrington J.K., and Belisle J.W. J. Org. Chem. 39 (1974) 1094
36. Blackburn G.M., and Turkmen H. Org. Biomol. Chem. 3 (2005) 225
37. Amarasinghe K.K.D., Evidokimov A.G., Xu K., Clark C.M., Maier M.B., Srivastava A., Colson A.-O., Gerwe G.S., Stake G.E., Howard B.W., Pokross M.E., Gray J.L., and Peters K.G. Bioorg. Med. Chem. Lett. 16 (2006) 4252
38. Xin Z., liu G., Abad-Zapatero C., Pei Z., Szczepankiewicz B.G., Li X., Zhang T., Hutchins C.W., Hajduk P.J., Ballron S.J., Stashko M.A., Lubben T.H., Trevillyan J.M., and Jirousek M.R. Bioorg. Med. Chem. Lett. 16 (2006) 4252
39. Liu G., Xin Z., Pei Z., Hajduk P.J., Abad-Zapatero C., Hutchins C.W., Zhao H., Lubben T.H., Ballron S.J., Haasch D.L., Kaszubska W., Rondinone C.M., Trevillyan J.M., and Jirousek M.R. J. Med. Chem. 46 (2003) 4232
40. Erlanson, D. A.; McDowell, R. S.; He, M. M.; Randal, M.; Simmons, R. L.; Kung, J.; Waight, A.; Hansen, S. K.
41. Douty B., Wayland B., Ala P.J., Bower M.J., Pruitt J., Bostrom L., Wei M., Klabe R., Gonneville L., Wynn R., Burn T.C., Liu P.C.C., Combs A.P., and Yue E.W. Bioorg. Med. Chem. Lett. 18 (2008) 66 and references therein
42. Gilbert A.M., Katz T.J., Geiger W.E., Robben M.P., and Reingold A.L. J. Am. Chem. Soc. 115 (1993) 3199
43. A pFLAG plasmid expressing the catalytic domain (residues 1-298) of human PTP1B was expressed in BL21 (DE3) cells and purified according to a two-step purification protocol (Cibracon blue affinity column and Sepharose Q anion exchange column) previously described by Asante-Appiah et al. See:. Asante-Appiah E., Ball K., Bateman K., Skorey K., Friesen R., Desponts C., Payette P., Bayly C., Zamboni R., Scapin G., Ramachandran C., Kennedy B.P. J. Biol. Chem. 276 (2001) 26036